Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941378 | 0.90 | PRKD1 (0.46) | PRKD1TBK1ABL1RIN1ATR | |
| SCHEMBL14027862 | 0.81 | PRKD1 (0.45) | PRKD1ABL1ATRKDM4EL3MBTL1 | |
| SCHEMBL4936182 | 0.78 | NPC1 (0.38) | ABL1MTORKDM4EL3MBTL1 | |
| SCHEMBL14027879 | 0.76 | ABL1 (0.38) | ABL1MTORKDM4EL3MBTL1 | |
| SCHEMBL4936238 | 0.74 | MKNK1 (0.46) | ABL1MTORKDM4EL3MBTL1 | |
| SCHEMBL4939332 | 0.73 | AVPR1A (0.40) | ABL1 | |
| SCHEMBL4937180 | 0.72 | NPC1 (0.40) | ABL1MTORKDM4EL3MBTL1 | |
| SCHEMBL4933006 | 0.71 | PRKD1 (0.39) | PRKD1KDM4EJAK2 | |
| SCHEMBL4938205 | 0.71 | NPC1 (0.40) | BDKRB1ABL1MTOR | |
| SCHEMBL14027870 | 0.71 | TLR7 (0.38) | ABL1MTORKDM4EL3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | PDE4D 745/4885PRKD1 400/4885BDKRB1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.